The Experts below are selected from a list of 9 Experts worldwide ranked by ideXlab platform
B. Charbonnel - One of the best experts on this subject based on the ideXlab platform.
-
B Cell-adherent splenocytes precede the onset of diabetes in low-dose streptozotocin-treated mice
Diabetologia, 1990Co-Authors: B. Feve, J. P. Segain, B. CharbonnelAbstract:Splenocytes from low-dose (40 mg·kg^−1 day^−1) streptozotocin-treated mice were tested for their binding ability to rat insulinoma (RINm-5F) Cells in a Rosette-Forming Cell assay, before and during the onset of diabetes. They displayed a higher ( p
Otmar D. Wiestler - One of the best experts on this subject based on the ideXlab platform.
-
Microtubule-associated protein-2 immunoreactivity: a useful tool in the differential diagnosis of low-grade neuroepithelial tumors
Acta Neuropathologica, 2004Co-Authors: Ingmar Blümcke, Susanna Müller, Rolf Buslei, Beat M. Riederer, Otmar D. WiestlerAbstract:Complex and variable morphological phenotypes pose a major challenge to the histopathological classification of neuroepithelial tumors. This applies in particular for low-grade gliomas and glio-neuronal tumors. Recently, we and others have identified microtubule-associated protein-2 (MAP2) as an immunohistochemical marker expressed in the majority of glial tumors. Characteristic Cell morphologies can be recognized by MAP2 immunoreactivity in different glioma entities, i.e., process sparse oligodendroglial versus densely ramified astrocytic elements. Here, we describe MAP2-immunoreactivity patterns in a large series of various neuroepithelial tumors and related neoplasms ( n =960). Immunohistochemical analysis led to the following conclusions: (1) specific pattern of MAP2-positive tumor Cells can be identified in 95% of glial neoplasms; (2) ependymal tumors do not express MAP2 in their Rosette-Forming Cell component; (3) tumors of the pineal gland as well as malignant embryonic tumors are also characterized by abundant MAP2 immunoreactivity; (4) virtually no MAP2 expression can be observed in the neoplastic glial component of glio-neuronal tumors, i.e. gangliogliomas; (5) malignant glial tumor variants (WHO grade III or IV) exhibit different and less specific MAP2 staining patterns compared to their benign counterparts (WHO grade I or II); (6) with the exception of melanomas and small Cell lung cancers, MAP2 expression is very rare in metastatic and non-neuroepithelial tumors; (7) glial MAP2 expression was not detected in 56 non-neoplastic lesions. These data point towards MAP2 as valuable diagnostic tool for pattern recognition and differential diagnosis of low-grade neuroepithelial tumors.
B. Feve - One of the best experts on this subject based on the ideXlab platform.
-
B Cell-adherent splenocytes precede the onset of diabetes in low-dose streptozotocin-treated mice
Diabetologia, 1990Co-Authors: B. Feve, J. P. Segain, B. CharbonnelAbstract:Splenocytes from low-dose (40 mg·kg^−1 day^−1) streptozotocin-treated mice were tested for their binding ability to rat insulinoma (RINm-5F) Cells in a Rosette-Forming Cell assay, before and during the onset of diabetes. They displayed a higher ( p
Ingmar Blümcke - One of the best experts on this subject based on the ideXlab platform.
-
Microtubule-associated protein-2 immunoreactivity: a useful tool in the differential diagnosis of low-grade neuroepithelial tumors
Acta Neuropathologica, 2004Co-Authors: Ingmar Blümcke, Susanna Müller, Rolf Buslei, Beat M. Riederer, Otmar D. WiestlerAbstract:Complex and variable morphological phenotypes pose a major challenge to the histopathological classification of neuroepithelial tumors. This applies in particular for low-grade gliomas and glio-neuronal tumors. Recently, we and others have identified microtubule-associated protein-2 (MAP2) as an immunohistochemical marker expressed in the majority of glial tumors. Characteristic Cell morphologies can be recognized by MAP2 immunoreactivity in different glioma entities, i.e., process sparse oligodendroglial versus densely ramified astrocytic elements. Here, we describe MAP2-immunoreactivity patterns in a large series of various neuroepithelial tumors and related neoplasms ( n =960). Immunohistochemical analysis led to the following conclusions: (1) specific pattern of MAP2-positive tumor Cells can be identified in 95% of glial neoplasms; (2) ependymal tumors do not express MAP2 in their Rosette-Forming Cell component; (3) tumors of the pineal gland as well as malignant embryonic tumors are also characterized by abundant MAP2 immunoreactivity; (4) virtually no MAP2 expression can be observed in the neoplastic glial component of glio-neuronal tumors, i.e. gangliogliomas; (5) malignant glial tumor variants (WHO grade III or IV) exhibit different and less specific MAP2 staining patterns compared to their benign counterparts (WHO grade I or II); (6) with the exception of melanomas and small Cell lung cancers, MAP2 expression is very rare in metastatic and non-neuroepithelial tumors; (7) glial MAP2 expression was not detected in 56 non-neoplastic lesions. These data point towards MAP2 as valuable diagnostic tool for pattern recognition and differential diagnosis of low-grade neuroepithelial tumors.
J. P. Segain - One of the best experts on this subject based on the ideXlab platform.
-
B Cell-adherent splenocytes precede the onset of diabetes in low-dose streptozotocin-treated mice
Diabetologia, 1990Co-Authors: B. Feve, J. P. Segain, B. CharbonnelAbstract:Splenocytes from low-dose (40 mg·kg^−1 day^−1) streptozotocin-treated mice were tested for their binding ability to rat insulinoma (RINm-5F) Cells in a Rosette-Forming Cell assay, before and during the onset of diabetes. They displayed a higher ( p
